Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities

D. De; A. Kaushik; S. Handa; R. Mahajan; E. Schmidt

doi:10.1111/jdv.17229

Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities

D. De^*, A. Kaushik, S. Handa, R. Mahajan, E. Schmidt

^*Korrespondierende/r Autor/-in für diese Arbeit

Institut für Experimentelle Dermatologie

Postgraduate Institute of Medical Education and Research

21 Zitate (Scopus)

Originalsprache	Englisch
Zeitschrift	Journal of the European Academy of Dermatology and Venereology
Jahrgang	35
Ausgabenummer	7
Seiten (von - bis)	e469-e472
Seitenumfang	4
ISSN	0926-9959
DOIs	https://doi.org/10.1111/jdv.17229
Publikationsstatus	Veröffentlicht - 07.2021

Fördermittel

The study was supported in part by structural funds of the Clinical Research Unit Pemphigoid Diseases (KFO 303) and the Cluster of Excellence Precision Medicine in Chronic Inflammation (EXC 2167) both funded by Deutsche Forschungsgemeinschaft. We are grateful to Ms Shilpa for immunological investigations and Vanessa Krull, L?beck, for excellent technical assistance with the IgE-specific BP180 and BP230 ELISA. The study was supported in part by structural funds of the Clinical Research Unit (KFO 303) and the Cluster of Excellence Precision Medicine in Chronic Inflammation (EXC 2167) both funded by Deutsche Forschungsgemeinschaft. We are grateful to Ms Shilpa for immunological investigations and Vanessa Krull, Lübeck, for excellent technical assistance with the IgE‐specific BP180 and BP230 ELISA. Pemphigoid Diseases

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)

Dokumente

10.1111/jdv.17229

Weitere Links

Zitieren

@article{536609ecbfca4cd88980a7e9085fb3e6,

title = "Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities",

author = "D. De and A. Kaushik and S. Handa and R. Mahajan and E. Schmidt",

note = "Funding Information: The study was supported in part by structural funds of the Clinical Research Unit Pemphigoid Diseases (KFO 303) and the Cluster of Excellence Precision Medicine in Chronic Inflammation (EXC 2167) both funded by Deutsche Forschungsgemeinschaft. We are grateful to Ms Shilpa for immunological investigations and Vanessa Krull, L?beck, for excellent technical assistance with the IgE-specific BP180 and BP230 ELISA. Funding Information: The study was supported in part by structural funds of the Clinical Research Unit (KFO 303) and the Cluster of Excellence Precision Medicine in Chronic Inflammation (EXC 2167) both funded by Deutsche Forschungsgemeinschaft. We are grateful to Ms Shilpa for immunological investigations and Vanessa Krull, L{\"u}beck, for excellent technical assistance with the IgE‐specific BP180 and BP230 ELISA. Pemphigoid Diseases ",

year = "2021",

month = jul,

doi = "10.1111/jdv.17229",

language = "English",

volume = "35",

pages = "e469--e472",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "John Wiley and Sons Inc",

number = "7",

}

TY - JOUR

T1 - Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities

AU - De, D.

AU - Kaushik, A.

AU - Handa, S.

AU - Mahajan, R.

AU - Schmidt, E.

N1 - Funding Information: The study was supported in part by structural funds of the Clinical Research Unit Pemphigoid Diseases (KFO 303) and the Cluster of Excellence Precision Medicine in Chronic Inflammation (EXC 2167) both funded by Deutsche Forschungsgemeinschaft. We are grateful to Ms Shilpa for immunological investigations and Vanessa Krull, L?beck, for excellent technical assistance with the IgE-specific BP180 and BP230 ELISA. Funding Information: The study was supported in part by structural funds of the Clinical Research Unit (KFO 303) and the Cluster of Excellence Precision Medicine in Chronic Inflammation (EXC 2167) both funded by Deutsche Forschungsgemeinschaft. We are grateful to Ms Shilpa for immunological investigations and Vanessa Krull, Lübeck, for excellent technical assistance with the IgE‐specific BP180 and BP230 ELISA. Pemphigoid Diseases

PY - 2021/7

Y1 - 2021/7

UR - https://www.scopus.com/pages/publications/85103202558

UR - https://www.mendeley.com/catalogue/ffff6a1e-5921-334a-8cfb-40e4f9018aaa/

U2 - 10.1111/jdv.17229

DO - 10.1111/jdv.17229

M3 - Letters

C2 - 33725360

AN - SCOPUS:85103202558

SN - 0926-9959

VL - 35

SP - e469-e472

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 7

ER -